Page last updated: 2024-08-21

1-naphthylisothiocyanate and End Stage Liver Disease

1-naphthylisothiocyanate has been researched along with End Stage Liver Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Dai, M; Liu, A; Luo, Y; Xu, G; Xu, L; Yang, J; Zhang, H	1

Other Studies

1 other study(ies) available for 1-naphthylisothiocyanate and End Stage Liver Disease

Article	Year
Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling. Pharmacological reports : PR, 2020, Volume: 72, Issue:4 Topics: 1-Naphthylisothiocyanate; Animals; Chemokine CCL2; Chemokine CXCL2; Chemotaxis; Cholestasis; End Stage Liver Disease; Fenofibrate; Hypolipidemic Agents; MAP Kinase Signaling System; Mice; Mice, 129 Strain; Mice, Knockout	2020

Article

Year

Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling.

Pharmacological reports : PR, 2020, Volume: 72, Issue:4

Topics: 1-Naphthylisothiocyanate; Animals; Chemokine CCL2; Chemokine CXCL2; Chemotaxis; Cholestasis; End Stage Liver Disease; Fenofibrate; Hypolipidemic Agents; MAP Kinase Signaling System; Mice; Mice, 129 Strain; Mice, Knockout

2020